1. Home
  2. DSP vs BDTX Comparison

DSP vs BDTX Comparison

Compare DSP & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

HOLD

Current Price

$10.99

Market Cap

213.3M

Sector

Technology

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$1.66

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSP
BDTX
Founded
1999
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
213.3M
171.9M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
DSP
BDTX
Price
$10.99
$1.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
7
Target Price
$17.81
$9.67
AVG Volume (30 Days)
303.0K
2.3M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
157.14
130.71
EPS
N/A
N/A
Revenue
$344,201,000.00
N/A
Revenue This Year
$20.27
N/A
Revenue Next Year
$16.88
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.00
N/A
52 Week Low
$8.11
$1.66
52 Week High
$15.18
$4.94

Technical Indicators

Market Signals
Indicator
DSP
BDTX
Relative Strength Index (RSI) 44.45 30.23
Support Level $9.68 N/A
Resistance Level $11.23 $2.30
Average True Range (ATR) 0.90 0.13
MACD -0.17 -0.04
Stochastic Oscillator 8.51 2.17

Price Performance

Historical Comparison
DSP
BDTX

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: